DexCom
DXCM
728 hedge funds and large institutions have $40.5B invested in DexCom in 2021 Q2 according to their latest regulatory filings, with 85 funds opening new positions, 316 increasing their positions, 201 reducing their positions, and 77 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 316 | Existing positions reduced: 201
55% more call options, than puts
Call options by funds: $930M | Put options by funds: $599M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
22% more capital invested
Capital invested by funds: $33.1B → $40.5B (+$7.41B)
11.23% more ownership
Funds ownership: 381.14% → 392.37% (+11%)
10% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 77
0% less funds holding
Funds holding: 730 → 728 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$398M |
| 2 |
Janus Henderson Group
London,
|
+$384M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$346M |
| 4 |
JP Morgan Chase
New York
|
+$338M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$208M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$403M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$313M |
| 3 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$194M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$153M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$116M |
DXCM Hedge Fund Activity: Q2 2021 in Review
728 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q2 2021, worth a combined $40.5B — up 22% from $33.1B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new DXCM positions and 77 closed out — a net gain of 8 holders — while 316 added to existing stakes and 201 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $398M. The largest seller was Fidelity Investments, cutting an estimated $403M.
- 728 institutional investors held DexCom (DXCM) as of Q2 2021, down from 730 in Q1 2021.
- Funds reported $40.5B of DexCom stock for Q2 2021, up 22% quarter-over-quarter.
- 85 funds opened new DexCom positions in Q2 2021 and 77 closed out, a net change of +8 holders.
- The largest DexCom buyer in Q2 2021 was Capital Research Global Investors, an estimated $398M added.
- The largest DexCom seller in Q2 2021 was Fidelity Investments, an estimated $403M sold.
Based on aggregated 13F filings for Q2 2021.